<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(Suppl )</volume><submitter>Garcia-Manero G</submitter><journal>HemaSphere</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9642083</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS</pubmed_title><pmcid>PMC9642083</pmcid><pubmed_authors>Zhou L</pubmed_authors><pubmed_authors>Lane M</pubmed_authors><pubmed_authors>Platzbecker U</pubmed_authors><pubmed_authors>Li C</pubmed_authors><pubmed_authors>Winer E</pubmed_authors><pubmed_authors>Groepper S</pubmed_authors><pubmed_authors>Dugan J</pubmed_authors><pubmed_authors>Sallman D</pubmed_authors><pubmed_authors>Giagounidis A</pubmed_authors><pubmed_authors>Metzeler K</pubmed_authors><pubmed_authors>Garcia-Manero G</pubmed_authors><pubmed_authors>Bohme M</pubmed_authors><pubmed_authors>Kubasch A</pubmed_authors><pubmed_authors>Verma A</pubmed_authors><pubmed_authors>DeAngelo D</pubmed_authors><pubmed_authors>von Roemeling R</pubmed_authors><pubmed_authors>Tarantolo S</pubmed_authors><pubmed_authors>Gotze K</pubmed_authors><pubmed_authors>Martinez E</pubmed_authors></additional><is_claimable>false</is_claimable><name>S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS</name><description/><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-26T13:11:18.903Z</modification><creation>2025-02-19T04:37:55.591Z</creation></dates><accession>S-EPMC9642083</accession><cross_references/></HashMap>